1
Week 5 National STD Curriculum
Joshua Berroya
Chamberlain University
NR 568: Advanced Pharmacology for Care of the Family
Assignment Date
, TANIC SELF ASSESSMENT 2
TIGER-based Assessment of Nursing Informatics Competencies
CHLAMYDIA
• Chlamydia is the most common reportable bacterial sexually transmitted infection
in the United States, with approximately 1.75 million cases reported in 2018.
• The peak incidence of chlamydia infections in the United States occurs in females
aged 15 to 24 years.
• Chlamydia trachomatis causes a wide range of clinical manifestations, including
cervicitis, urethritis, pelvic inflammatory disease, infertility, pelvic pain, and
perihepatitis in women, and urethritis and epididymitis in men. Other manifestations
in men and women may include conjunctivitis, oropharyngeal infection,
proctitis/proctocolitis, and reactive arthritis.
• Infants born to mothers with untreated C. trachomatis infection may
develop conjunctivitis, trachoma, pneumonia, and urogenital infection.
• Screening for chlamydia in asymptomatic persons significantly reduces the
incidence of chlamydia-associated complications and is recommended in all sexually
active women younger than age 25, as well as in other persons at high risk of
infection.
• In most circumstances, the preferred diagnostic method for chlamydial infection is
with a C. trachomatis NAAT, which is FDA cleared for chlamydia testing on (1) male
and female urine samples, (2) male and female rectal and throat samples, (3)
clinician- collected endocervical, vaginal, and male urethral samples, and (4) self-
collected vaginal swabs if obtained in a clinical setting.
• Standard treatment for genital chlamydial infections in nonpregnant females and
all males is with single-dose azithromycin or a 7-day course of twice-daily
doxycycline.
• Persons who are diagnosed with chlamydia should receive counseling about the
nature of infection, transmission, and risk reduction, and their sex partners should
be referred for treatment; expedited partner therapy should be considered where
permitted.
• Treatment: Azithromycin
GONORRHEA
SCREENING FOR GONOCOCCAL INFECTION
Week 5 National STD Curriculum
Joshua Berroya
Chamberlain University
NR 568: Advanced Pharmacology for Care of the Family
Assignment Date
, TANIC SELF ASSESSMENT 2
TIGER-based Assessment of Nursing Informatics Competencies
CHLAMYDIA
• Chlamydia is the most common reportable bacterial sexually transmitted infection
in the United States, with approximately 1.75 million cases reported in 2018.
• The peak incidence of chlamydia infections in the United States occurs in females
aged 15 to 24 years.
• Chlamydia trachomatis causes a wide range of clinical manifestations, including
cervicitis, urethritis, pelvic inflammatory disease, infertility, pelvic pain, and
perihepatitis in women, and urethritis and epididymitis in men. Other manifestations
in men and women may include conjunctivitis, oropharyngeal infection,
proctitis/proctocolitis, and reactive arthritis.
• Infants born to mothers with untreated C. trachomatis infection may
develop conjunctivitis, trachoma, pneumonia, and urogenital infection.
• Screening for chlamydia in asymptomatic persons significantly reduces the
incidence of chlamydia-associated complications and is recommended in all sexually
active women younger than age 25, as well as in other persons at high risk of
infection.
• In most circumstances, the preferred diagnostic method for chlamydial infection is
with a C. trachomatis NAAT, which is FDA cleared for chlamydia testing on (1) male
and female urine samples, (2) male and female rectal and throat samples, (3)
clinician- collected endocervical, vaginal, and male urethral samples, and (4) self-
collected vaginal swabs if obtained in a clinical setting.
• Standard treatment for genital chlamydial infections in nonpregnant females and
all males is with single-dose azithromycin or a 7-day course of twice-daily
doxycycline.
• Persons who are diagnosed with chlamydia should receive counseling about the
nature of infection, transmission, and risk reduction, and their sex partners should
be referred for treatment; expedited partner therapy should be considered where
permitted.
• Treatment: Azithromycin
GONORRHEA
SCREENING FOR GONOCOCCAL INFECTION
